January 10, 2011 |
One of red blood cells' remarkable characteristics, among many, is their ability to deform and squish their way through blood vessels -- even blood vessels tinier than they are -- to deliver oxygen throughout the body. Scientists believe this flexibility contributes to red blood cells' ability to circulate for an average of 120 days. Now researchers at the University of North Carolina have synthesized red blood cell-sized and -shaped nanoparticles that mimic this flexibility and longevity.
October 25, 2010 |
In the "True Blood" television series, sexy vampires quaff bottles of artificial blood that allow them to live alongside humans in polite society. In real life, people in distress need artificial blood, and scientists are working on several synthetic concoctions that could stand in for the crucial body fluid. Every year, 4.5 million Americans receive lifesaving transfusions, according to the New York Blood Center, and 1 in 3 people will need blood at some point in their lifetime.
CALIFORNIA | LOCAL
March 9, 2009 |
Dr. Robert Winslow, a UC San Diego researcher who was one of the pioneers in the development of artificial blood, died at his home Feb. 2 after a long battle with brain cancer. He was 67. Winslow also had climbed Mt. Everest and worked briefly at a variety of high-altitude research laboratories to better understand the physiology of blood under such extreme conditions.
April 29, 2008 |
Despite evidence that a group of experimental blood substitutes nearly tripled the risk of heart attacks and caused a 30% increase in deaths, the Food and Drug Administration continued to approve some clinical trials of the products, researchers said Monday. The agency should have known about the risks by 2000 and halted all trials, thereby preventing deaths that have occurred in the last seven years, according to a report published online by the Journal of the American Medical Assn.
December 20, 2006 |
Shares of Northfield Laboratories Inc. lost more than half their value after the company said that more deaths occurred among patients given its synthetic blood product than among those not receiving the treatment in a study. There were 46 deaths among 349 patients receiving the product, called PolyHeme, compared with 35 among 363 people getting a standard treatment, Northfield said Tuesday.
June 18, 2001 |
For decades, scientists have chased the elusive dream of creating artificial blood--blood that would be universally compatible and readily available--and today a handful of U.S. companies is tantalizingly close to the finish line. Experts predict that the first generation of so-called fake blood could hit the market within two years, easing the blood shortage, saving lives during medical emergencies and further reducing the potential dangers from infectious diseases carried by donor blood.